This review describes recent advances in our understanding of the genetic heterogeneity, pathophysiology and treatment of Bartter syndrome, a group of autosomal recessive disorders that are characterized by markedly reduced or absent salt transport by the thick ascending limb of Henle. Consequently, individuals with Bartter syndrome exhibit renal salt wasting and lowered blood pressure, hypokalemic metabolic alkalosis and hypercalciuria with a variable risk of renal stones.
Introduction
Bartter syndrome is a group of rare autosomal-recessive disorders with a unifying pathophysiology consisting of severe reductions in, or losses of, salt absorption by the thick ascending limb of Henle (TAL). The characteristic phenotype of Bartter syndrome is renal salt wasting, hypokalemic metabolic alkalosis, and elevated renin and aldosterone levels, with normal or low blood pressure, although phenotypic variability has been observed [1] . Many individuals with Bartter syndrome also have elevated urinary calcium excretion and may develop nephrocalcinosis. Mutations in five genes that are expressed in the TAL have been identified in Bartter syndrome, and the products of these genes either transport salt (three genes, types I-III [2, 3, 4 . . ,5,6 . . ]) or regulate salt transport (two genes to be described in this review, types IV and V; Fig. 1 ). Loss-of-function mutations in three transporter genes had previously been identified and are ( Fig. 1) : type I Bartter syndrome, with mutations in the sodium-potassium-chloride cotransporter gene (SLC12A1 [7] ); type II Bartter syndrome, with mutations in the ROMK (or Kir1.1) potassium ion channel gene (KCNJ1 [8] [9] [10] [11] ); and type III Bartter syndrome, with mutations in the CLC-Kb chloride ion channel gene (Clcnk [12, 13] ). All three genetic variants are found in antenatal Bartter syndrome (also called hyperprostaglandin E syndrome), characterized by the additional features of maternal polyhydramnios, prematurity, severe polyuria and very elevated levels of prostaglandin E 2 in the blood and urine. The treatment of individuals with antenatal Bartter syndrome with the cyclooxygenase inhibitor, indomethacin, significantly improves both child development and treatment with salt and fluids. The two transport regulator genes causing Bartter syndrome are recent discoveries and are described in the next section.
Mouse knockout models of type I [14] and type II [15] Bartter syndrome have been produced, and both exhibit severe salt wasting and polyuria associated with hydronephrosis and renal insufficiency. In both models, the high postnatal mortality of more than 95% within the first 2 weeks, and renal insufficiency resulting from hydronephrosis in survivors, make study difficult and complicates the interpretation of pathophysiological observations. Recently, a ROMK (type II) knockout mouse was developed that exhibits high (425%) survival rates, and only exhibits mild or absent hydronephrosis, which should provide a good model for the study of Bartter syndrome pathophysiology and treatment [16 . ].
CLC chloride ion channels and Bartter syndrome type III
The CLC family (Clcn genes) of chloride ion channels consists of nine members that form anion pores in plasma membranes or in the membranes of intracellular organelles (e.g. endocytic vesicles [6 . . , 17, 18] ). The Xray crystal structure of a bacterial CLC channel has been solved, and reveals a homodimeric protein with each subunit containing a pore (often referred to as a doublebarrelled channel [19 . . ] ). Two members of the CLC family are predominately expressed in the kidney, ClC-Ka and ClC-Kb (ClC-K1 and ClC-K2, respectively, in rodents [6 . . , [20] [21] [22] ). These two genes probably arose by gene duplication and exhibit more than 90% sequence identity [6 . . ]. The details of the distribution of ClC-K channels along the nephron are still debated. However, in rat kidney, both ClC-K1 and ClC-K2 transcripts appear to be expressed in the TAL, distal convoluted tubule (DCT), connecting tubule (CNT)/cortical collecting duct, and outer medullary collecting duct, whereas exclusive expression of the ClC-K1 transcript is limited to the thin ascending limb and inner medullar collecting duct [6 . . ,22,23 . . , 24, 25] . Antibody staining, however, has revealed ClC-K1 protein expression only in thin ascending limbs with an apical and basolateral membrane pattern, consistent with the high chloride ion permeability of this nephron segment [22] . The mouse ClC-K1 (Clcnk1[ 7/7 ]) knockout exhibits nephrogenic diabetes insipidus without salt wasting predicted from ClC-K1 function in the thin ascending limb [26] . ClC-K2 is expressed in the lateral membranes of the TAL and more distal nephron segments, where the thiazidesensitive sodium-chloride co-transporter (DCT and early connecting segment) is expressed [22, 25] . ClC-K2 mediates transepithelial chloride ion transport in these distal nephron segments. In-situ hybridization and antibody studies suggest that ClC-K2 is expressed in type A intercalated cells in the collecting duct [25] . CLC-K expression is altered by salt and water intake, consistent with the roles of this chloride ion channel in salt and water handling by the kidney [6 . . ] . A recent study [24] showed that ClC-K2 messenger RNA in the rat medullary TAL is upregulated by furosemide and down-regulated by chronic high salt intake, consistent with a role for ClC-K2 in medullary TAL adaptation to varying salt intake.
The type III Bartter syndrome (ClC-K2) phenotype is highly variable and may present either as a typical antenatal variant or as a 'classic' Bartter variant char- Each Bartter type is associated with a specific gene that encodes the protein whose name is indicated in each square. Apical sodium ion (Na + ), potassium ion (K + ) and chloride ion (Cl) entry is mediated by the bumetanide-sensitive sodium-potassium-chloride co-transporter (NKCC2, SLC12A1 gene) and is driven by the electrochemical gradients set up by basolateral Na + ,K + -ATPase. Potassium recycles back into the luminal fluid via the ROMK channel (KCNJ1 gene) and chloride ion exits into the basolateral (interstitial) fluid through the ClC-Ka and ClC-Kb channels, where barttin functions as a b-subunit that is crucial for the trafficking of the ClC-K channels to the plasma membrane. The majority of basolateral chloride ion exit occurs via the ClC-Kb channel. The movement of potassium ions into the luminal fluid and chloride ions into the basolateral fluid establishes the lumenpositive transepithelial voltage that drives 50% of the sodium ion and all of the calcium ion and magnesium ion (Mg 2+ ) absorption. Activation of the extracellular calcium ion-sensing receptor (CaSR) inhibits the activity of NKCC2, ROMK and Na + ,K + -ATPase. Gain-of-function mutations in CaSR thus result in reductions in salt transport by the thick ascending limb of Henle (TAL; furosemide-like effect) that can cause the Bartter phenotype.
acterized by an onset in early childhood and less severe or absent hypercalciuria and nephrocalcinosis [13] . Given the distribution of ClC-K2(-Kb) in both the TAL and more distal nephron segments, including the DCT and CNT, loss-of-function mutations in ClC-Kb (Bartter type III, Fig. 1 ) might be expected to alter salt transport in both the TAL and DCT/CNT. The DCT and early CNT express the SLC12A3 gene encoding the thiazidesensitive, apical sodium-chloride co-transporter. ClC-Kb has been suggested to mediate basolateral chloride ion exit crucial to salt absorption by the DCT and early CNT. Loss-of-function mutations in SLC12A3 give rise to another autosomal recessive disorder referred to as Gitelman syndrome [7] . Gitelman syndrome is characterized by the same renal salt wasting, hypokalemic metabolic alkalosis and lowered blood pressure as Bartter types I-V, but is distinct from Bartter syndrome in having a low renal calcium excretion level. The Gitelman phenotype is similar to 'classic' Bartter syndrome in having a milder form of salt wasting and an onset in early childhood. Two recent studies [27,28 . ] showed that many individuals with type III Bartter syndrome exhibit a mixed Bartter-Gitelman phenotype consistent with the role of this chloride ion channel in both the TAL and DCT. This overlap between Bartter and Gitelman syndromes may account for the initial confusion in differentiating between these two syndromes. Interestingly to date, only ClC-Kb mutations have been identified in African Americans with Bartter syndrome [29] .
Bartter syndrome type IV
Barttin is a b-subunit of ClC-K channels and loss-offunction mutations in barttin cause Bartter syndrome with sensorineural deafness -Bartter type IV. A major conundrum was how ClC-K chlorine ion channels were regulated because the expression of these channels in Xenopus laevis oocytes produces no current (ClC-K2(Kb) gives no current whereas ClC-K1(Ka) gives at best only small anion current in oocytes [30] Whereas loss-of-function mutations in ClC-Kb generally cause a mild Bartter phenotype (Fig. 1) , mutations in barttin produce a severe Bartter phenotype with extreme growth retardation, severe renal salt wasting and poor responsiveness to indomethacin. The likely explanation for the differences in the severity of Bartter between the ClC-Kb and barttin mutations is that barttin mutations would result in a loss of ClC-K activity in all nephron segments expressing either or both of the two ClC-K channels. The severity of type IV Bartter syndrome would be consistent with both ClC-Ka and ClC-Kb contributing to basolateral chlorine ion exit in the TAL with the expression of ClC-Kb being greater than ClC-Ka (Figure 1 [23 . . ]). The latter would account for: (1) ClC-Kb mutations causing mild Bartter syndrome (some ClC-Ka activity would be present in the TAL to mediate basolateral chloride ion exit); (2) ClC-Ka mutant mice exhibiting little-to-no renal salt wasting (ClC-Kb is highly expressed in the TAL and DCT and would mediate the bulk of basolateral chloride ion exit); and (3) the observed ClC-K transcript and protein distributions along the nephron. Further studies will be necessary to verify this theory.
Sensorineural deafness is specific for barttin (type IV), and not ClC-Kb (type III), associated Bartter syndrome. This specificity can be explained by the role of the ClC-K/barttin channels in the inner ear. The secretion of the potassium ion-rich endolymph by marginal cells in the stria vascularis of the inner ear is required for the normal function of the inner hair cells mediating hearing (Fig. 2  [6 . . ,35] ). Both ClC-K channel genes are expressed in marginal cells, and barttin is required for the function of the ClC-K channels (Fig. 2 [6 . . ,32]). Recently, the ClC-Kb gene promoter has been shown to drive EGFP (enhanced green fluorescent protein) expression in the inner ear [34] . Loss-of-function mutations in ClC-Kb would not be expected to eliminate endolymph production because the ClC-Ka/barttin channels would be functional. However, barttin mutations will eliminate both ClC-Ka and ClC-Kb channel activities required for endolymph production in the scala media of the inner ear and thereby result in deafness.
Bartter syndrome type V
Gain-of-function mutations in the extracellular calcium ion-sensing receptor (CaSR) cause Bartter syndrome type V. A second new gene causing Bartter syndrome has also enhanced our understanding of the regulation of salt transport by the TAL. The CaSR is a G proteincoupled surface receptor that belongs to family C of the G protein receptor superfamily [36] . The CaSR functions importantly in divalent mineral homeostasis, and both loss-of-function and gain-of-function mutations in the CaSR cause familial hypercalcemic hypocalciuria and autosomal-dominant hypocalcemia, respectively [36] .
The CaSR is activated by increases in extracellular calcium ion concentrations, and the EC 50 for calcium ion can be modified by extracellular polyamines and amino acids [36] . We had previously shown that the CaSR was highly expressed on the basolateral membranes of the TAL [37, 38] , and that activation of this G proteincoupled receptor inhibited salt transport (a furosemidelike effect; Fig. 1 [36,39] ). Two recent studies [40 . . ,41 . . ] have now identified individuals with gainof-function mutations in the CaSR (autosomal-dominant hypocalcemia) that result in a Bartter phenotype.
Cyclooxygenase in Bartter syndrome
Antenatal Bartter syndrome is associated with elevated renin, angiotensin II and prostaglandin E 2 levels in plasma and elevated renal excretion of prostaglandin E 2 .
Elevated prostaglandin E 2 is thought to contribute to or aggravate prematurity and failure to thrive, as well as salt and water loss leading to volume depletion and dehydration. Consistent with this theory, the treatment of many Bartter syndrome patients with cyclooxygenase inhibitors such as indomethacin reduces the severity of the Bartter symptoms and corrects childhood growth. Indomethacin inhibits both cyclooxygenase 1 and cyclooxygenase 2 isoforms. Cyclooxygenase 1 is expressed in principal cells and can modulate salt and water absorption stimulated by vasopressin. Cyclooxygenase 2 is expressed in rat macula densa cells and is involved in glomerular-tubular feedback (GTF), which adjusts glomerular filtration according to the distal tubular (macula densa) flow rate. As in TAL cells, both NKCC2 and ROMK (Fig. 1) are required for solute transport into macula densa cells, which is thought to be necessary for sensing distal flow.
Renal salt wasting is reduced in mice with loss-offunction mutations in protein that mediate salt and water transport in the proximal tubule (e.g. sodium-hydrogen exchanger, aquaporin-1) by activation of the macula densa sensor of the GTF system. The high distal flow stimulates GTF, thereby lowering the nephron glomerular filtration rate. The activated GTF has been suggested to be an important adaptive response [42] .
In contrast, individuals with Bartter syndrome would have reduced or absent GTF as a result of the loss of macula densa sensing.
Cyclooxygenase 2 expression in rats is upregulated by salt deprivation, and cyclooxygenase 2 is required for enhanced renin release from the glomerular afferent arteriole. In fact, abundant cyclooxygenase 2 has been demonstrated in macula densa cells in renal biopsy specimens from individuals with Bartter syndrome and may represent a response to the chronic volume depletion [43] . Recently, three reports have examined the effects of cyclooxygenase 2-specific inhibitors in individuals with hyperprostaglandin E type Bartter syndrome [44,45,46 . ]. The studies demonstrated that the elevated prostaglandin E 2 and renin levels characteristic of antenatal Bartter syndrome were dependent on cyclooxygenase 2 activity. Diuresis and calcium excretion were significantly reduced by cyclooxygenase 2 inhibition [44,45,46 . ].
Vascular reactivity in Bartter syndrome
Individuals with Bartter syndrome also exhibit vascular hyporeactivity associated with increased endothelial isoform of nitric oxide synthase (eNOS) and nitric oxide (NO) formation. The elevated eNOS may be caused by abnormal cell signaling, with reduced protein kinase C activation that is required for enhanced extracellular nitric oxide synthase expression. A recent report showed the reduced expression of Gaq in Bartter syndrome [47] , which could account for the blunting of protein kinase C production and the upregulation of the nitric oxide system. In another study [48] , increased urinary and plasma nitrite levels were found in children with Bartter The sodium-potassium-chloride co-transporter, NKCC1, mediates potassium ion (K + ) entry into the cell across the basolateral membrane, which is ultimately secreted into the endolymph via the KCNQ1/KCNE1 potassium ion channel in the apical membranes. The recycling of both sodium ions (Na + ) and chloride ions (Cl) back into the basolateral fluid via Na + ,K + -ATPase and the ClC-K chloride ion channels, respectively, is crucial for maintaining basolateral potassium ion entry via NKCC2. Barttin is a b-subunit for both ClC-K channels, and is required for trafficking of the chloride ion channels to the plasma membrane. Loss-of-function mutations in barttin thus abolish basolateral chloride ion channel activity, resulting in the inability to secrete potassium ions into the endolymph, and accounts for the sensorineural deafness in type IV Bartter syndrome. As either ClC-Ka or ClC-Kb can mediate chloride ion recycling, mutations in ClC-Kb in type III Bartter syndrome are not associated with deafness.
syndrome. The latter study also showed that another endogenous vasodilator, adrenomedullin, may also be increased in these children with Bartter syndrome and may contribute to vascular hyporeactivity.
Conclusion
Mutations in five genes have now been shown to cause Bartter syndrome, associated with alterations in salt transport by the TAL. Three genes encode ion transporters crucial to sodium chloride absorption by the TAL, and two new genes have been identified that function as regulators of salt transporters. Loss-offunction mutations in the new b-subunit of the ClC-K chloride ion channels leads to the reduced surface expression of the CLC-K chloride ion channels in the TAL and more distal nephron segments and in the marginal cells of the inner ear. The former causes a severe Bartter phenotype and the latter the sensorineural deafness that characterizes the barttin type IV Bartter syndrome. Severe activating mutations of the extracellular CaSR can also cause Bartter syndrome by inhibiting sodium chloride transport by the TAL. The latter further supports the important role of this CaSR in regulating salt and divalent mineral transport in the TAL. Even with these new findings, we may not have identified all of the Bartter-causing genes; more insights into salt transport and the regulation in the distal nephron await the identification of such genes.
